

Jennifer Kahler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10208135/jennifer-kahler-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10
papers

537
citations

6
h-index

11
g-index

11
ext. papers

604
ext. citations

5.8
avg, IF

2.24
L-index

#	Paper	IF	Citations
10	Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021 , 27, 622-631	12.9	3
9	Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. <i>Clinical Cancer Research</i> , 2016 , 22, 383-94	12.9	16
8	Novel DNA-Damaging Linker Payloads Are Active in Models of Acquired Resistance to Calicheamicin and Standard of Care. <i>Blood</i> , 2016 , 128, 3522-3522	2.2	
7	Lysosomes and Antibody-Drug Conjugates 2016 , 409-421		
6	Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 4511-6	2.9	19
5	Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013 , 23, 4381-7	2.9	12
4	Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011 , 21, 2092-7	2.9	16
3	Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1394-406	6.1	150
2	High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay. <i>Assay and Drug Development Technologies</i> , 2009 , 7, 471-8	2.1	5
1	Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. <i>Cancer Research</i> , 2006 , 66, 8163-71	10.1	315